ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells.

ImaginAb is an emerging imaging company focused on immune-oncology. The technology also helps in targeting and visualizing CD8+ T cells, which are activated by the immunotherapy and induce cell death.

Under the terms of the agreement, the collaborators will advance the current ImaginAb-sponsored clinical trials that aim to study the utility and value of CD8 ImmunoPet in the immune-oncology pipeline.

In return, collaborators will gain access to data of clinical and imaging data that will help them analyse the post-clinical results.

ImaginAb’s is developing Minibodies that preserve their whole length while being inert in the body. Advancing the pipeline of minibodies to target cancer, including CD8 ImmunoPET targeting CD8 T cells, the company believes its products can add quality to the lives of cancer patients.

The company is already working with major pharma players such as Merck & Co., Boehringer Ingelheim, Nektar and Roche, some of the major players in cancer immunotherapy, backed by venture capital firms including The Parker Institute for Cancer Immunotherapy, Nextech Invest, Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group.

Aytu BioScience enters into an agreement with Cerecor to gain access to a portfolio of prescription products for USD 17 Million.

The transaction will be done in two modes in cash worth USD 4.5 Million and USD 12.5 Million worth stocks.  This agreement will add approximately USD 44 Million to the revenue of Aytu BioSciences. The revenue is also added by the previous acquisition of Innovus Pharmaceuticals.

The acquired assets consist of six established primary pediatric care products including: AcipHex Sprinkle, Cefaclor for Oral Suspension, Karbinal ER, Flexichamber, Poly-Vi-Flor and Tri-Vi-Flor.

Aytu BioSciences is a company aiming to commercialize novel products to address patients’ needs, committed to treating problems like hypogonadism, severe cough and respiratory symptoms, insomnia, and male infertility.

Akorn, a leading pharmaceutical firm, has recently received a new Abbreviated New Drug Application (ANDA) approval the FDA for its betamethasone dipropionate lotion.

According to IQVIA, U.S. sales of betamethasone dipropionate lotion (augmented), 0.05% were approximately $10 million for the twelve months ended August 2019.

Betamethasone dipropionate lotion, a strong corticosteroid, is used to treat several types of skin conditions like eczema, dermatitis, allergies, rash. Indicated to provide relief from inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older, it is manufactured at Akorn’s Amityville, New York manufacturing facility.